Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.65 |
| ▸ | PPARA | Q07869 | 11/20 | 0.65 |
| ▸ | PPARG | P37231 | 8/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480573 | 0.90 | PPARD (0.67) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL5480585 | 0.81 | PPARD (0.79) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5478068 | 0.81 | PPARD (0.67) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL4673657 | 0.81 | PPARD (0.70) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL6235596 | 0.80 | PPARD (0.72) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL5654049 | 0.80 | PPARD (0.68) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL4679628 | 0.80 | PPARD (0.68) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL5477014 | 0.80 | PPARD (0.71) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL5512034 | 0.79 | PPARD (0.57) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL6716382 | 0.79 | PPARD (0.66) | PPARDPPARAPPARGFFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190079-A1 | METHODS FOR THE SELECTIVE MODULATION OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070190079-A1 | METHODS FOR THE SELECTIVE MODULATION OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070190079-A1 | METHODS FOR THE SELECTIVE MODULATION OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190079-A1 | METHODS FOR THE SELECTIVE MODULATION OF PPAR | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.